Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 2/20 | 0.47 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.47 |
| ▸ | AR | P10275 | 6/20 | 0.43 |
| ▸ | SLC22A12 | Q96S37 | 4/20 | 0.38 |
| ▸ | IDH1 | O75874 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10781954 | 0.80 | IDO1 (0.52) | IMPDH2IMPDH1ARSLC22A12KDM4E | |
| SCHEMBL29489135 | 0.80 | IMPDH2 (0.64) | IMPDH2IMPDH1ARSLC22A12KDM4E | |
| SCHEMBL151936 | 0.80 | IMPDH2 (0.64) | IMPDH2IMPDH1ARSLC22A12KDM4E | |
| SCHEMBL13611705 | 0.78 | PABPC1 (0.51) | IMPDH2IMPDH1ARSLC22A12IDH1 | |
| SCHEMBL5241397 | 0.78 | GAA (0.51) | IMPDH2IMPDH1ARSLC22A12KDM4E | |
| SCHEMBL11193357 | 0.78 | IMPDH2 (0.61) | IMPDH2IMPDH1ARSLC22A12KDM4E | |
| SCHEMBL28191022 | 0.77 | MAPT (0.43) | IMPDH2IMPDH1ARSLC22A12KDM4E | |
| SCHEMBL13448504 | 0.76 | IDO1 (0.56) | IMPDH2IMPDH1ARSLC22A12IDH1 | |
| SCHEMBL11228244 | 0.75 | IMPDH2 (0.59) | IMPDH2IMPDH1ARKDM4EGAA | |
| SCHEMBL12343769 | 0.74 | IDO1 (0.46) | IMPDH2IMPDH1ARSLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114874197-B | Viscosity fluorescent probe capable of targeting multiple organelles | 郑州大学 | 2023-04-25 | — | — | CN | disclosed |
| EP-1553074-B1 | FUSED BENZENE DERIVATIVE AND USE | TAKEDA PHARMACEUTICAL (JP) | 2014-06-18 | — | — | EP | disclosed |
| US-7649001-B2 | Fused benzene derivative and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-19 | — | — | US | disclosed |
| US-20060106067-A1 | Fused benzene derivative and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-05-18 | — | — | US | disclosed |
| CN-1688527-A | Fused benzene derivatives and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2005-10-26 | — | — | CN | disclosed |
| EP-1553074-A1 | FUSED BENZENE DERIVATIVE AND USE | Takeda Pharmaceutical Company Limited (JP) | 2005-07-13 | — | — | EP | disclosed |
| EP-0894799-B1 | INDOLOMORPHINANE DERIVATIVES AND REMEDIES/PREVENTIVES FOR CEREBRAL DISORDERS | TORAY INDUSTRIES (JP) | 2004-04-07 | — | — | EP | disclosed |
| US-6156762-A | Indolomorphinan derivative and agent for curing and preventing cerebral disorder | TORAY INDUSTRIES, INC. (JP) | 2000-12-05 | — | — | US | disclosed |
| EP-0647629-B1 | Neurotensin active substituted 1-naphthylpyrazole-3-carboxamides, their preparation and pharmaceutical compositions containing them | SANOFI SA (FR) | 1999-07-07 | — | — | EP | disclosed |
| EP-0894799-A1 | INDOLOMORPHINANE DERIVATIVES AND REMEDIES/PREVENTIVES FOR CEREBRAL DISORDERS | TORAY INDUSTRIES, INC. (JP) | 1999-02-03 | — | — | EP | disclosed |
| US-5585497-A | USEFUL IN TREATMENT OF NEUROPSYCHIATRIC DISORDERS, ESPECIALLY THOSE ASSOCIATED WITH A DYSFUNCTION OF THE DOPAMINERGIC SYSTEMS | SANOFI (FR) | 1996-12-17 | — | — | US | disclosed |
| US-5523455-A | PREPARED USING A NAPHTHYLHYDRAZINE CHEMICAL INTERMEDIATE | SANOFI (FR) | 1996-06-04 | — | — | US | disclosed |
| US-5502059-A | DOPAMINERGIC DYSFUNCTION DISORDERS | SANOFI (FR) | 1996-03-26 | — | — | US | disclosed |
| EP-0647629-A1 | Neurotensin active substituted 1-naphthylpyrazole-3-carboxamides, their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 1995-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106067-A1 | Fused benzene derivative and use | AR, NR5A1, CBR3 | IMPDH2 4239/4885IMPDH1 4294/4885AR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.